Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline ofin vivotherapies across a broad range of autoimmune and oncology indications, today announced an upcoming presentation at the American College of Rheumatology (ACR) Annual Meeting being held October 24-29, 2025, in Chicago, Illinois. This dataset is a broader update on Orna's lead program, ORN-252, as it continues toward clinical entry in the first half of 2026.
Presentation Details (encore):
Title: In VivopanCAR™ Therapy Utilizing Circular RNA for the Treatment of Autoimmune Diseases Speaker: Isin Dalkilic-Liddle, Ph.D., Vice President, Head of Discovery Sciences, Orna TherapeuticsDate/Time: Monday, October 27, 2025, 10:30 AM – 12:30 PM CDTSession Name: (0934-0954) Systemic Lupus Erythematosus – Animal Models PosterLocation: Hall F1
AboutOrna TherapeuticsOrna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based delivery systems and comprehensive editing programs position Orna to advance novel RNA medicines with vast potential to transform patient care. To learn more, visitwww.ornatx.comand follow Orna Therapeutics onXandLinkedIn.
Orna Therapeutics Investor Contact:Alex LoboPrecision AQAlex.lobo@precisionaq.com
https://edge.prnewswire.com/c/img/favicon.png?sn=NY05990&sd=2025-10-24
View original content:https://www.prnewswire.com/news-releases/orna-therapeutics-announces-encore-presentation-at-the-american-college-of-rheumatology-annual-meeting-supporting-its-in-vivo-car-therapy-approach-in-autoimmune-diseases-302593353.html
SOURCE Orna Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=NY05990&Transmission_Id=202510240800PR_NEWS_USPR_____NY05990&DateId=20251024